PTN

SEC source: 0001654954-22-014133 · section16.xml · nonDerivative · entry 6

WILLS STEPHEN T · CIK 0001103883 · Executive VP and CFO/COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 375,461

F1 · shares: A certificate of amendment of the articles of incorporation of Palatin Technologies for a 1-for-25 reverse stock split of issued and outstanding common stock (the "Reverse Stock Split") was effective as of 5:00 p.m. Eastern Time on August 30, 2022 (the "Effective Date"). All share and per share numbers herein, including common stock and awards made or vested prior to the Effective Date, have been adjusted to give effect to the Reverse Stock Split.

F7 · shares: Shares withheld by the issuer, on election of the Reporting Person with the consent of the issuer, to pay employee withholding taxes. Such taxes were withheld and reported for the payroll in the period ended October 25, 2022 (for the October 28, 2022 payroll), with the per share value determined as of June 24, 2022, the date of vesting. The grant of the underlying 2,020 time-based restricted share units which vested on June 24, 2022 was reported on Form 4 filed on June 26, 2019.

F1 · price: A certificate of amendment of the articles of incorporation of Palatin Technologies for a 1-for-25 reverse stock split of issued and outstanding common stock (the "Reverse Stock Split") was effective as of 5:00 p.m. Eastern Time on August 30, 2022 (the "Effective Date"). All share and per share numbers herein, including common stock and awards made or vested prior to the Effective Date, have been adjusted to give effect to the Reverse Stock Split.

F7 · price: Shares withheld by the issuer, on election of the Reporting Person with the consent of the issuer, to pay employee withholding taxes. Such taxes were withheld and reported for the payroll in the period ended October 25, 2022 (for the October 28, 2022 payroll), with the per share value determined as of June 24, 2022, the date of vesting. The grant of the underlying 2,020 time-based restricted share units which vested on June 24, 2022 was reported on Form 4 filed on June 26, 2019.

SEC source: 0001654954-22-014133 · section16.xml · nonDerivative · entry 5

WILLS STEPHEN T · CIK 0001103883 · Executive VP and CFO/COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 376,015

F1 · shares: A certificate of amendment of the articles of incorporation of Palatin Technologies for a 1-for-25 reverse stock split of issued and outstanding common stock (the "Reverse Stock Split") was effective as of 5:00 p.m. Eastern Time on August 30, 2022 (the "Effective Date"). All share and per share numbers herein, including common stock and awards made or vested prior to the Effective Date, have been adjusted to give effect to the Reverse Stock Split.

F6 · shares: Shares withheld by the issuer, on election of the Reporting Person with the consent of the issuer, to pay employee withholding taxes. Such taxes were withheld and reported for the payroll in the period ended October 25, 2022 (for the October 28, 2022 payroll), with the per share value determined as of June 22, 2022, the date of vesting. The grant and vesting of the underlying 1,626 restricted share units was reported on Form 4 filed on June 28, 2022, with a transaction date of June 22, 2022.

F1 · price: A certificate of amendment of the articles of incorporation of Palatin Technologies for a 1-for-25 reverse stock split of issued and outstanding common stock (the "Reverse Stock Split") was effective as of 5:00 p.m. Eastern Time on August 30, 2022 (the "Effective Date"). All share and per share numbers herein, including common stock and awards made or vested prior to the Effective Date, have been adjusted to give effect to the Reverse Stock Split.

F6 · price: Shares withheld by the issuer, on election of the Reporting Person with the consent of the issuer, to pay employee withholding taxes. Such taxes were withheld and reported for the payroll in the period ended October 25, 2022 (for the October 28, 2022 payroll), with the per share value determined as of June 22, 2022, the date of vesting. The grant and vesting of the underlying 1,626 restricted share units was reported on Form 4 filed on June 28, 2022, with a transaction date of June 22, 2022.

SEC source: 0001654954-22-014133 · section16.xml · nonDerivative · entry 4

WILLS STEPHEN T · CIK 0001103883 · Executive VP and CFO/COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 376,461

F1 · shares: A certificate of amendment of the articles of incorporation of Palatin Technologies for a 1-for-25 reverse stock split of issued and outstanding common stock (the "Reverse Stock Split") was effective as of 5:00 p.m. Eastern Time on August 30, 2022 (the "Effective Date"). All share and per share numbers herein, including common stock and awards made or vested prior to the Effective Date, have been adjusted to give effect to the Reverse Stock Split.

F5 · shares: Shares withheld by the issuer, on election of the Reporting Person with the consent of the issuer, to pay employee withholding taxes. Such taxes were withheld and reported for the payroll in the period ended October 25, 2022 (for the October 28, 2022 payroll), with the per share value determined as of June 22, 2022, the date of vesting. The grant and vesting of the underlying 1,441 restricted share units was reported on Form 4 filed on June 24, 2022, with a transaction date of June 22, 2022.

F1 · price: A certificate of amendment of the articles of incorporation of Palatin Technologies for a 1-for-25 reverse stock split of issued and outstanding common stock (the "Reverse Stock Split") was effective as of 5:00 p.m. Eastern Time on August 30, 2022 (the "Effective Date"). All share and per share numbers herein, including common stock and awards made or vested prior to the Effective Date, have been adjusted to give effect to the Reverse Stock Split.

F5 · price: Shares withheld by the issuer, on election of the Reporting Person with the consent of the issuer, to pay employee withholding taxes. Such taxes were withheld and reported for the payroll in the period ended October 25, 2022 (for the October 28, 2022 payroll), with the per share value determined as of June 22, 2022, the date of vesting. The grant and vesting of the underlying 1,441 restricted share units was reported on Form 4 filed on June 24, 2022, with a transaction date of June 22, 2022.

SEC source: 0001654954-22-014133 · section16.xml · nonDerivative · entry 3

WILLS STEPHEN T · CIK 0001103883 · Executive VP and CFO/COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 376,856

F1 · shares: A certificate of amendment of the articles of incorporation of Palatin Technologies for a 1-for-25 reverse stock split of issued and outstanding common stock (the "Reverse Stock Split") was effective as of 5:00 p.m. Eastern Time on August 30, 2022 (the "Effective Date"). All share and per share numbers herein, including common stock and awards made or vested prior to the Effective Date, have been adjusted to give effect to the Reverse Stock Split.

F4 · shares: Shares withheld by the issuer, on election of the Reporting Person with the consent of the issuer, to pay employee withholding taxes. Such taxes were withheld and reported for the payroll in the period ended October 25, 2022 (for the October 28, 2022 payroll), with the per share value determined as of June 22, 2022, the date of vesting. The grant of the underlying 6,090 time-based restricted share units, which vested on June 22, 2022, was reported on Form 4 filed on June 24, 2021.

F1 · price: A certificate of amendment of the articles of incorporation of Palatin Technologies for a 1-for-25 reverse stock split of issued and outstanding common stock (the "Reverse Stock Split") was effective as of 5:00 p.m. Eastern Time on August 30, 2022 (the "Effective Date"). All share and per share numbers herein, including common stock and awards made or vested prior to the Effective Date, have been adjusted to give effect to the Reverse Stock Split.

F4 · price: Shares withheld by the issuer, on election of the Reporting Person with the consent of the issuer, to pay employee withholding taxes. Such taxes were withheld and reported for the payroll in the period ended October 25, 2022 (for the October 28, 2022 payroll), with the per share value determined as of June 22, 2022, the date of vesting. The grant of the underlying 6,090 time-based restricted share units, which vested on June 22, 2022, was reported on Form 4 filed on June 24, 2021.

SEC source: 0001654954-22-014133 · section16.xml · nonDerivative · entry 2

WILLS STEPHEN T · CIK 0001103883 · Executive VP and CFO/COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 378,526

F1 · shares: A certificate of amendment of the articles of incorporation of Palatin Technologies for a 1-for-25 reverse stock split of issued and outstanding common stock (the "Reverse Stock Split") was effective as of 5:00 p.m. Eastern Time on August 30, 2022 (the "Effective Date"). All share and per share numbers herein, including common stock and awards made or vested prior to the Effective Date, have been adjusted to give effect to the Reverse Stock Split.

F3 · shares: Shares withheld by the issuer, on election of the Reporting Person with the consent of the issuer, to pay employee withholding taxes. Such taxes were withheld and reported for the payroll in the period ended October 25, 2022 (for the October 28, 2022 payroll), with the per share value determined as of June 16, 2022, the date of vesting. The grant and vesting of the underlying 5,097 restricted share units was reported on Form 4 filed on June 24, 2022, with a transaction date of June 22, 2022.

F1 · price: A certificate of amendment of the articles of incorporation of Palatin Technologies for a 1-for-25 reverse stock split of issued and outstanding common stock (the "Reverse Stock Split") was effective as of 5:00 p.m. Eastern Time on August 30, 2022 (the "Effective Date"). All share and per share numbers herein, including common stock and awards made or vested prior to the Effective Date, have been adjusted to give effect to the Reverse Stock Split.

F3 · price: Shares withheld by the issuer, on election of the Reporting Person with the consent of the issuer, to pay employee withholding taxes. Such taxes were withheld and reported for the payroll in the period ended October 25, 2022 (for the October 28, 2022 payroll), with the per share value determined as of June 16, 2022, the date of vesting. The grant and vesting of the underlying 5,097 restricted share units was reported on Form 4 filed on June 24, 2022, with a transaction date of June 22, 2022.

SEC source: 0001654954-22-014133 · section16.xml · nonDerivative · entry 1

WILLS STEPHEN T · CIK 0001103883 · Executive VP and CFO/COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 379,924

F1 · shares: A certificate of amendment of the articles of incorporation of Palatin Technologies for a 1-for-25 reverse stock split of issued and outstanding common stock (the "Reverse Stock Split") was effective as of 5:00 p.m. Eastern Time on August 30, 2022 (the "Effective Date"). All share and per share numbers herein, including common stock and awards made or vested prior to the Effective Date, have been adjusted to give effect to the Reverse Stock Split.

F2 · shares: Shares withheld by the issuer, on election of the Reporting Person with the consent of the issuer, to pay employee withholding taxes. Such taxes were withheld and reported for the payroll in the period ended October 25, 2022 (for the October 28, 2022 payroll), with the per share value determined as of June 16, 2022, the date of vesting. The grant of the underlying 5,570 time-based restricted share units, which vested on June 16, 2022, was reported on Form 4 filed on June 18, 2020 as to one half of the total grant, and on Form 4 filed on June 26, 2020 as to the remaining one half, which had been granted contingent on increasing the shares reserved for grant under the 2011 Stock Incentive Plan, which was approved the stockholders at a meeting on June 25, 2020.

F1 · price: A certificate of amendment of the articles of incorporation of Palatin Technologies for a 1-for-25 reverse stock split of issued and outstanding common stock (the "Reverse Stock Split") was effective as of 5:00 p.m. Eastern Time on August 30, 2022 (the "Effective Date"). All share and per share numbers herein, including common stock and awards made or vested prior to the Effective Date, have been adjusted to give effect to the Reverse Stock Split.

F2 · price: Shares withheld by the issuer, on election of the Reporting Person with the consent of the issuer, to pay employee withholding taxes. Such taxes were withheld and reported for the payroll in the period ended October 25, 2022 (for the October 28, 2022 payroll), with the per share value determined as of June 16, 2022, the date of vesting. The grant of the underlying 5,570 time-based restricted share units, which vested on June 16, 2022, was reported on Form 4 filed on June 18, 2020 as to one half of the total grant, and on Form 4 filed on June 26, 2020 as to the remaining one half, which had been granted contingent on increasing the shares reserved for grant under the 2011 Stock Incentive Plan, which was approved the stockholders at a meeting on June 25, 2020.

SEC source: 0001654954-22-008910 · section16.xml · derivative · entry 3

WILLS STEPHEN T · CIK 0001103883 · Executive VP and CFO/COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 186,375

Underlying: Common Stock · 186,375 shares

Expires 2031-06-22

F3 · derivative.exercise_date: Stock options granted under the Plan, each of which represents the right to receive, upon payment of the exercise price, one share of common stock. On June 22, 2021, the Company granted performance-based options to its executive officers which were contingent upon an increase in common stock available for issuance under the Plan, which increase was approved by our stockholders on June 24, 2022. The Compensation Committee certified on June 22, 2022, contingent upon approval of an increase in common stock available under the Plan, that a defined performance objective as to 75% of the target number of stock option shares for the fiscal year ending June 30, 2022 had been achieved, based on performance criteria relating to advancement of melanocortin receptor-1 programs, including initiation of clinical trials, and progress in commercialization of Vyleesi.

SEC source: 0001654954-22-008910 · section16.xml · derivative · entry 2

WILLS STEPHEN T · CIK 0001103883 · Executive VP and CFO/COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 497,000

Underlying: Common Stock · 497,000 shares

Expires 2031-06-22

F2 · derivative.exercise_date: Stock options granted under the Plan, each of which represents the right to receive, upon payment of the exercise price, one share of common stock. On June 22, 2021, the Company granted time-based options to its executive officers which vest at the rate of 25% per year, starting in June 2022, contingent upon an increase in common stock available for issuance under the Plan, which increase was approved by our stockholders on June 24, 2022

SEC source: 0001654954-22-008910 · section16.xml · nonDerivative · entry 1

WILLS STEPHEN T · CIK 0001103883 · Executive VP and CFO/COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,360,658

F1 · shares: Restricted share units granted under the 2011 Stock Incentive Plan (the "Plan"), each of which represents the right to receive, without further payment, one share of common stock. On June 22, 2021, the Company granted performance-based restricted stock units to its executive officers which were contingent upon an increase in common stock available for issuance under the Plan, which increase was approved by our stockholders on June 24, 2022. The Compensation Committee certified on June 22, 2022, contingent upon approval of an increase in common stock available under the Plan, that a defined performance objective as to 75% of the target number of share units for the fiscal year ending June 30, 2022 had been achieved, based on performance criteria relating to advancement of melanocortin receptor-1 programs, including initiation of clinical trials, and progress in commercialization of Vyleesi.

F1 · price: Restricted share units granted under the 2011 Stock Incentive Plan (the "Plan"), each of which represents the right to receive, without further payment, one share of common stock. On June 22, 2021, the Company granted performance-based restricted stock units to its executive officers which were contingent upon an increase in common stock available for issuance under the Plan, which increase was approved by our stockholders on June 24, 2022. The Compensation Committee certified on June 22, 2022, contingent upon approval of an increase in common stock available under the Plan, that a defined performance objective as to 75% of the target number of share units for the fiscal year ending June 30, 2022 had been achieved, based on performance criteria relating to advancement of melanocortin receptor-1 programs, including initiation of clinical trials, and progress in commercialization of Vyleesi.

SEC source: 0001654954-22-008909 · section16.xml · derivative · entry 3

SPANA CARL · CIK 0001042011 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 215,625

Underlying: Common Stock · 215,625 shares

Expires 2031-06-22

F3 · derivative.exercise_date: Stock options granted under the Plan, each of which represents the right to receive, upon payment of the exercise price, one share of common stock. On June 22, 2021, the Company granted performance-based options to its executive officers which were contingent upon an increase in common stock available for issuance under the Plan, which increase was approved by our stockholders on June 24, 2022. The Compensation Committee certified on June 22, 2022, contingent upon approval of an increase in common stock available under the Plan, that a defined performance objective as to 75% of the target number of stock option shares for the fiscal year ending June 30, 2022 had been achieved, based on performance criteria relating to advancement of melanocortin receptor-1 programs, including initiation of clinical trials, and progress in commercialization of Vyleesi.

SEC source: 0001654954-22-008909 · section16.xml · derivative · entry 2

SPANA CARL · CIK 0001042011 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 575,000

Underlying: Common Stock · 575,000 shares

Expires 2031-06-22

F2 · derivative.exercise_date: Stock options granted under the Plan, each of which represents the right to receive, upon payment of the exercise price, one share of common stock. On June 22, 2021, the Company granted time-based options to its executive officers which vest at the rate of 25% per year, starting in June 2022, contingent upon an increase in common stock available for issuance under the Plan, which increase was approved by our stockholders on June 24, 2022.

SEC source: 0001654954-22-008909 · section16.xml · nonDerivative · entry 1

SPANA CARL · CIK 0001042011 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,526,458

F1 · shares: Restricted share units granted under the 2011 Stock Incentive Plan (the "Plan"), each of which represents the right to receive, without further payment, one share of common stock. On June 22, 2021, the Company granted performance-based restricted stock units to its executive officers which were contingent upon an increase in common stock available for issuance under the Plan, which increase was approved by our stockholders on June 24, 2022. The Compensation Committee certified on June 22, 2022, contingent upon approval of an increase in common stock available under the Plan, that a defined performance objective as to 75% of the target number of share units for the fiscal year ending June 30, 2022 had been achieved, based on performance criteria relating to advancement of melanocortin receptor-1 programs, including initiation of clinical trials, and progress in commercialization of Vyleesi.

F1 · price: Restricted share units granted under the 2011 Stock Incentive Plan (the "Plan"), each of which represents the right to receive, without further payment, one share of common stock. On June 22, 2021, the Company granted performance-based restricted stock units to its executive officers which were contingent upon an increase in common stock available for issuance under the Plan, which increase was approved by our stockholders on June 24, 2022. The Compensation Committee certified on June 22, 2022, contingent upon approval of an increase in common stock available under the Plan, that a defined performance objective as to 75% of the target number of share units for the fiscal year ending June 30, 2022 had been achieved, based on performance criteria relating to advancement of melanocortin receptor-1 programs, including initiation of clinical trials, and progress in commercialization of Vyleesi.

SEC source: 0001654954-22-008785 · section16.xml · derivative · entry 6

SPANA CARL · CIK 0001042011 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 245,105

Underlying: Common Stock · 245,105 shares

Expires 2030-06-16

F6 · derivative.exercise_date: Stock options granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, upon payment of the exercise price, one share of common stock. The performance condition stock option grant, made June 16, 2020, vested in part on June 22, 2022, upon certification by the Compensation Committee that a defined performance objective as to 75% of the target number of stock option shares for the fiscal year ending June 30, 2022 had been achieved, based on performance criteria relating to advancement of melanocortin receptor-1 programs, including initiation of clinical trials, and progress in commercialization of Vyleesi.

SEC source: 0001654954-22-008785 · section16.xml · derivative · entry 5

SPANA CARL · CIK 0001042011 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 677,000

Underlying: Common stock · 677,000 shares

Expires 2032-06-22

F5 · derivative.exercise_date: The options vest at the rate of 25% per year, starting on June 22, 2023.

SEC source: 0001654954-22-008785 · section16.xml · nonDerivative · entry 4

SPANA CARL · CIK 0001042011 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,482,930

F4 · shares: ) Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The performance condition grant, made June 22, 2021, vested in part on June 22, 2022, upon certification by the Compensation Committee that a defined performance objective as to 75% of the target number of share units for the fiscal year ending June 30, 2022 had been achieved, based on performance criteria relating to advancement of melanocortin receptor-1 programs, including initiation of clinical trials, and progress in commercialization of Vyleesi.

F4 · price: ) Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The performance condition grant, made June 22, 2021, vested in part on June 22, 2022, upon certification by the Compensation Committee that a defined performance objective as to 75% of the target number of share units for the fiscal year ending June 30, 2022 had been achieved, based on performance criteria relating to advancement of melanocortin receptor-1 programs, including initiation of clinical trials, and progress in commercialization of Vyleesi.

SEC source: 0001654954-22-008785 · section16.xml · nonDerivative · entry 3

SPANA CARL · CIK 0001042011 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,441,239

F3 · shares: Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The performance condition grant, made June 16, 2020, vested in part on June 22, 2022, upon certification by the Compensation Committee that a defined performance objective as to 75% of the target number of share units for the fiscal year ending June 30, 2022 had been achieved, based on performance criteria relating to advancement of melanocortin receptor-1 programs, including initiation of clinical trials, and progress in commercialization of Vyleesi.

F3 · price: Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The performance condition grant, made June 16, 2020, vested in part on June 22, 2022, upon certification by the Compensation Committee that a defined performance objective as to 75% of the target number of share units for the fiscal year ending June 30, 2022 had been achieved, based on performance criteria relating to advancement of melanocortin receptor-1 programs, including initiation of clinical trials, and progress in commercialization of Vyleesi.

SEC source: 0001654954-22-008785 · section16.xml · nonDerivative · entry 2

SPANA CARL · CIK 0001042011 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,293,352

F2 · shares: Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The performance condition grant, made June 24, 2019, vested in part on June 22, 2022, upon certification by the Compensation Committee that a defined performance objective as to 75% of the target number of share units for the fiscal year ending June 30, 2022 had been achieved, based on performance criteria relating to advancement of melanocortin receptor-1 programs, including initiation of clinical trials, and progress in commercialization of Vyleesi.

F2 · price: Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The performance condition grant, made June 24, 2019, vested in part on June 22, 2022, upon certification by the Compensation Committee that a defined performance objective as to 75% of the target number of share units for the fiscal year ending June 30, 2022 had been achieved, based on performance criteria relating to advancement of melanocortin receptor-1 programs, including initiation of clinical trials, and progress in commercialization of Vyleesi.

SEC source: 0001654954-22-008785 · section16.xml · nonDerivative · entry 1

SPANA CARL · CIK 0001042011 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,237,907

F1 · shares: Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The restricted share units vest at the rate of 25% per year, starting on June 22, 2023.

F1 · price: Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The restricted share units vest at the rate of 25% per year, starting on June 22, 2023.

SEC source: 0001654954-22-008783 · section16.xml · derivative · entry 2

Morris Arlene · CIK 0001362520 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 128,000

Underlying: Common Stock · 128,000 shares

Expires 2032-06-22

F2 · derivative.exercise_date: The options vest at the rate of 1/12 per month on the last day of each month, starting on July 31, 2022.

SEC source: 0001654954-22-008783 · section16.xml · nonDerivative · entry 1

Morris Arlene · CIK 0001362520 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 903,667

F1 · shares: Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The restricted share units vest on June 22, 2023.

F1 · price: Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The restricted share units vest on June 22, 2023.

SEC source: 0001654954-22-008784 · section16.xml · derivative · entry 6

WILLS STEPHEN T · CIK 0001103883 · Executive VP and CFO/COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 211,136

Underlying: Common Stock · 211,136 shares

Expires 2030-06-22

F6 · derivative.exercise_date: Stock options granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, upon payment of the exercise price, one share of common stock. The performance condition stock option grant, made June 16, 2020, vested in part on June 22, 2022, upon certification by the Compensation Committee that a defined performance objective as to 75% of the target number of stock option shares for the fiscal year ending June 30, 2022 had been achieved, based on performance criteria relating to advancement of melanocortin receptor-1 programs, including initiation of clinical trials, and progress in commercialization of Vyleesi.

SEC source: 0001654954-22-008784 · section16.xml · derivative · entry 5

WILLS STEPHEN T · CIK 0001103883 · Executive VP and CFO/COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 587,500

Underlying: Common Stock · 587,500 shares

Expires 2032-06-22

F5 · derivative.exercise_date: The options vest at the rate of 25% per year, starting on June 22, 2023.

SEC source: 0001654954-22-008784 · section16.xml · nonDerivative · entry 4

WILLS STEPHEN T · CIK 0001103883 · Executive VP and CFO/COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,319,999

F4 · shares: Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The performance condition grant, made June 22, 2021, vested in part on June 22, 2022, upon certification by the Compensation Committee that a defined performance objective as to 75% of the target number of share units for the fiscal year ending June 30, 2022 had been achieved, based on performance criteria relating to advancement of melanocortin receptor-1 programs, including initiation of clinical trials, and progress in commercialization of Vyleesi.

F4 · price: Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The performance condition grant, made June 22, 2021, vested in part on June 22, 2022, upon certification by the Compensation Committee that a defined performance objective as to 75% of the target number of share units for the fiscal year ending June 30, 2022 had been achieved, based on performance criteria relating to advancement of melanocortin receptor-1 programs, including initiation of clinical trials, and progress in commercialization of Vyleesi.

SEC source: 0001654954-22-008784 · section16.xml · nonDerivative · entry 3

WILLS STEPHEN T · CIK 0001103883 · Executive VP and CFO/COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,283,971

F3 · shares: Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The performance condition grant, made June 16, 2020, vested in part on June 22, 2022, upon certification by the Compensation Committee that a defined performance objective as to 75% of the target number of share units for the fiscal year ending June 30, 2022 had been achieved, based on performance criteria relating to advancement of melanocortin receptor-1 programs, including initiation of clinical trials, and progress in commercialization of Vyleesi.

F3 · price: Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The performance condition grant, made June 16, 2020, vested in part on June 22, 2022, upon certification by the Compensation Committee that a defined performance objective as to 75% of the target number of share units for the fiscal year ending June 30, 2022 had been achieved, based on performance criteria relating to advancement of melanocortin receptor-1 programs, including initiation of clinical trials, and progress in commercialization of Vyleesi.

SEC source: 0001654954-22-008784 · section16.xml · nonDerivative · entry 2

WILLS STEPHEN T · CIK 0001103883 · Executive VP and CFO/COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,156,557

F2 · shares: Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The performance condition grant, made June 24, 2019, vested in part on June 22, 2022, upon certification by the Compensation Committee that a defined performance objective as to 75% of the target number of share units for the fiscal year ending June 30, 2022 had been achieved, based on performance criteria relating to advancement of melanocortin receptor-1 programs, including initiation of clinical trials, and progress in commercialization of Vyleesi.

F2 · price: Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The performance condition grant, made June 24, 2019, vested in part on June 22, 2022, upon certification by the Compensation Committee that a defined performance objective as to 75% of the target number of share units for the fiscal year ending June 30, 2022 had been achieved, based on performance criteria relating to advancement of melanocortin receptor-1 programs, including initiation of clinical trials, and progress in commercialization of Vyleesi.

SEC source: 0001654954-22-008784 · section16.xml · nonDerivative · entry 1

WILLS STEPHEN T · CIK 0001103883 · Executive VP and CFO/COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,109,100

F1 · shares: Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The restricted share units vest at the rate of 25% per year, starting on June 22, 2023.

F1 · price: Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The restricted share units vest at the rate of 25% per year, starting on June 22, 2023.

SEC source: 0001654954-22-008782 · section16.xml · derivative · entry 2

Manning Anthony M. · CIK 0001716468 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 128,000

Underlying: Common Stock · 128,000 shares

Expires 2032-06-22

F2 · derivative.exercise_date: The options vest at the rate of 1/12 per month on the last day of each month, starting on July 31, 2022.

SEC source: 0001654954-22-008782 · section16.xml · nonDerivative · entry 1

Manning Anthony M. · CIK 0001716468 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 693,667

F1 · shares: Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The restricted share units vest on June 22, 2023.

F1 · price: Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The restricted share units vest on June 22, 2023.

SEC source: 0001654954-22-008781 · section16.xml · derivative · entry 2

PRENDERGAST JOHN K A · CIK 0001042019 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 173,000

Underlying: Common Stock · 173,000 shares

Expires 2032-06-22

F2 · derivative.exercise_date: The options vest at the rate of 1/12 per month on the last day of each month, starting on July 31, 2022.

SEC source: 0001654954-22-008781 · section16.xml · nonDerivative · entry 1

PRENDERGAST JOHN K A · CIK 0001042019 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,639,684

F1 · shares: Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The restricted share units vest on June 22, 2023.

SEC source: 0001654954-22-008780 · section16.xml · derivative · entry 2

DUNTON ALAN W · CIK 0001304773 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 128,000

Underlying: Common Stock · 128,000 shares

Expires 2032-06-22

F2 · derivative.exercise_date: The options vest at the rate of 1/12 per month on the last day of each month, starting on July 31, 2022.

SEC source: 0001654954-22-008780 · section16.xml · nonDerivative · entry 1

DUNTON ALAN W · CIK 0001304773 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 991,519

F1 · shares: Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The restricted share units vest on June 22, 2023.

F1 · price: Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The restricted share units vest on June 22, 2023.

SEC source: 0001654954-22-008779 · section16.xml · derivative · entry 2

Hull Joseph Stanley · CIK 0001338384 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 128,000

Underlying: Common Stock · 128,000 shares

Expires 2032-06-22

F2 · derivative.exercise_date: The options vest at the rate of 1/12 per month on the last day of each month, starting on July 31, 2022.

SEC source: 0001654954-22-008779 · section16.xml · nonDerivative · entry 1

Hull Joseph Stanley · CIK 0001338384 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 980,967

F1 · shares: Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The restricted share units vest on June 22, 2023.

F1 · price: Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The restricted share units vest on June 22, 2023.

SEC source: 0001654954-22-008778 · section16.xml · derivative · entry 2

DEVEER ROBERT K JR · CIK 0001158829 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 128,000

Underlying: Common Stock · 128,000 shares

Expires 2032-06-22

F2 · derivative.exercise_date: The options vest at the rate of 1/12 per month on the last day of each month, starting on July 31, 2022.

SEC source: 0001654954-22-008778 · section16.xml · nonDerivative · entry 1

DEVEER ROBERT K JR · CIK 0001158829 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,018,307

F1 · shares: Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The restricted share units vest on June 22, 2023.

F1 · price: Restricted share units granted under the 2011 Stock Incentive Plan, each of which represents the right to receive, without further payment, one share of common stock. The restricted share units vest on June 22, 2023.

SEC source: 0001654954-21-008929 · section16.xml · nonDerivative · entry 4

SPANA CARL · CIK 0001042011 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,552,677

F4 · shares: Shares withheld by the issuer, on election of the Reporting Person with the consent of the issuer, to pay employee withholding taxes. Such taxes were withheld and reported for the payroll in the period ended August 13, 2021 (for the August 15, 2021 payroll), with the per share value determined as of June 24, 2021, the date of vesting. The grant and vesting of the underlying 52,923 restricted share units was reported on Form 4 filed on June 24, 2021, with a transaction date of June 22, 2021.

F4 · price: Shares withheld by the issuer, on election of the Reporting Person with the consent of the issuer, to pay employee withholding taxes. Such taxes were withheld and reported for the payroll in the period ended August 13, 2021 (for the August 15, 2021 payroll), with the per share value determined as of June 24, 2021, the date of vesting. The grant and vesting of the underlying 52,923 restricted share units was reported on Form 4 filed on June 24, 2021, with a transaction date of June 22, 2021.

SEC source: 0001654954-21-008929 · section16.xml · nonDerivative · entry 3

SPANA CARL · CIK 0001042011 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,572,857

F3 · shares: Shares withheld by the issuer, on election of the Reporting Person with the consent of the issuer, to pay employee withholding taxes. Such taxes were withheld and reported for the payroll in the period ended August 13, 2021 (for the August 15, 2021 payroll), with the per share value determined as of June 24, 2021, the date of vesting. The grant of the underlying 59,000 time-based restricted share units which vested on June 24, 2021 was reported on Form 4 filed on June 26, 2019.

F3 · price: Shares withheld by the issuer, on election of the Reporting Person with the consent of the issuer, to pay employee withholding taxes. Such taxes were withheld and reported for the payroll in the period ended August 13, 2021 (for the August 15, 2021 payroll), with the per share value determined as of June 24, 2021, the date of vesting. The grant of the underlying 59,000 time-based restricted share units which vested on June 24, 2021 was reported on Form 4 filed on June 26, 2019.

SEC source: 0001654954-21-008929 · section16.xml · nonDerivative · entry 2

SPANA CARL · CIK 0001042011 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,595,354

F2 · shares: Shares withheld by the issuer, on election of the Reporting Person with the consent of the issuer, to pay employee withholding taxes. Such taxes were withheld and reported for the payroll in the period ended August 13, 2021 (for the August 15, 2021 payroll), with the per share value determined as of June 16, 2021, the date of vesting. The grant and vesting of the underlying 126,068 restricted share units was reported on Form 4 filed on June 24, 2021, with a transaction date of June 22, 2021.

F2 · price: Shares withheld by the issuer, on election of the Reporting Person with the consent of the issuer, to pay employee withholding taxes. Such taxes were withheld and reported for the payroll in the period ended August 13, 2021 (for the August 15, 2021 payroll), with the per share value determined as of June 16, 2021, the date of vesting. The grant and vesting of the underlying 126,068 restricted share units was reported on Form 4 filed on June 24, 2021, with a transaction date of June 22, 2021.

SEC source: 0001654954-21-008929 · section16.xml · nonDerivative · entry 1

SPANA CARL · CIK 0001042011 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,643,424

F1 · shares: Shares withheld by the issuer, on election of the Reporting Person with the consent of the issuer, to pay employee withholding taxes. Such taxes were withheld and reported for the payroll in the period ended August 13, 2021 (for the August 15, 2021 payroll), with the per share value determined as of June 16, 2021, the date of vesting. The grant of the underlying time-based restricted share units, which vest at the rate of 25% per year starting June 16, 2021, was reported on Form 4 filed on June 18, 2020 as to one half of the total grant, and on Form 4 filed on June 26, 2020 as to the remaining one half, which had been granted contingent on increasing the shares reserved for grant under the 2011 Stock Incentive Plan, which was approved the stockholders at a meeting on June 25, 2020.

F1 · price: Shares withheld by the issuer, on election of the Reporting Person with the consent of the issuer, to pay employee withholding taxes. Such taxes were withheld and reported for the payroll in the period ended August 13, 2021 (for the August 15, 2021 payroll), with the per share value determined as of June 16, 2021, the date of vesting. The grant of the underlying time-based restricted share units, which vest at the rate of 25% per year starting June 16, 2021, was reported on Form 4 filed on June 18, 2020 as to one half of the total grant, and on Form 4 filed on June 26, 2020 as to the remaining one half, which had been granted contingent on increasing the shares reserved for grant under the 2011 Stock Incentive Plan, which was approved the stockholders at a meeting on June 25, 2020.

SEC source: 0001654954-21-008931 · section16.xml · nonDerivative · entry 4

WILLS STEPHEN T · CIK 0001103883 · Executive VP and CFO/COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,640,464

F4 · shares: Shares withheld by the issuer, on election of the Reporting Person with the consent of the issuer, to pay employee withholding taxes. Such taxes were withheld and reported for the payroll in the period ended August 13, 2021 (for the August 15, 2021 payroll), with the per share value determined as of June 24, 2021, the date of vesting. The grant and vesting of the underlying 45,199 restricted share units was reported on Form 4 filed on June 24, 2021, with a transaction date of June 22, 2021.

F4 · price: Shares withheld by the issuer, on election of the Reporting Person with the consent of the issuer, to pay employee withholding taxes. Such taxes were withheld and reported for the payroll in the period ended August 13, 2021 (for the August 15, 2021 payroll), with the per share value determined as of June 24, 2021, the date of vesting. The grant and vesting of the underlying 45,199 restricted share units was reported on Form 4 filed on June 24, 2021, with a transaction date of June 22, 2021.

SEC source: 0001654954-21-008931 · section16.xml · nonDerivative · entry 3

WILLS STEPHEN T · CIK 0001103883 · Executive VP and CFO/COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,652,885

F3 · shares: Shares withheld by the issuer, on election of the Reporting Person with the consent of the issuer, to pay employee withholding taxes. Such taxes were withheld and reported for the payroll in the period ended August 13, 2021 (for the August 15, 2021 payroll), with the per share value determined as of June 24, 2021, the date of vesting. The grant of the underlying 50,500 time-based restricted share units which vested on June 24, 202, was reported on Form 4 filed on June 26, 2019.

F3 · price: Shares withheld by the issuer, on election of the Reporting Person with the consent of the issuer, to pay employee withholding taxes. Such taxes were withheld and reported for the payroll in the period ended August 13, 2021 (for the August 15, 2021 payroll), with the per share value determined as of June 24, 2021, the date of vesting. The grant of the underlying 50,500 time-based restricted share units which vested on June 24, 202, was reported on Form 4 filed on June 26, 2019.

SEC source: 0001654954-21-008931 · section16.xml · nonDerivative · entry 2

WILLS STEPHEN T · CIK 0001103883 · Executive VP and CFO/COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,666,732

F2 · shares: Shares withheld by the issuer, on election of the Reporting Person with the consent of the issuer, to pay employee withholding taxes. Such taxes were withheld and reported for the payroll in the period ended August 13, 2021 (for the August 15, 2021 payroll), with the per share value determined as of June 16, 2021, the date of vesting. The grant and vesting of the underlying 108,615 restricted share units was reported on Form 4 filed on June 24, 2021, with a transaction date of June 22, 2021.

F2 · price: Shares withheld by the issuer, on election of the Reporting Person with the consent of the issuer, to pay employee withholding taxes. Such taxes were withheld and reported for the payroll in the period ended August 13, 2021 (for the August 15, 2021 payroll), with the per share value determined as of June 16, 2021, the date of vesting. The grant and vesting of the underlying 108,615 restricted share units was reported on Form 4 filed on June 24, 2021, with a transaction date of June 22, 2021.

SEC source: 0001654954-21-008931 · section16.xml · nonDerivative · entry 1

WILLS STEPHEN T · CIK 0001103883 · Executive VP and CFO/COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,696,514

F1 · shares: Shares withheld by the issuer, on election of the Reporting Person with the consent of the issuer, to pay employee withholding taxes. Such taxes were withheld and reported for the payroll in the period ended August 13, 2021 (for the August 15, 2021 payroll), with the per share value determined as of June 16, 2021, the date of vesting. The grant of the underlying time-based restricted share units, which vest at the rate of 25% per year starting June 16, 2021, was reported on Form 4 filed on June 18, 2020 as to one half of the total grant, and on Form 4 filed on June 26, 2020 as to the remaining one half, which had been granted contingent on increasing the shares reserved for grant under the 2011 Stock Incentive Plan, which was approved the stockholders at a meeting on June 25, 2020.

F1 · price: Shares withheld by the issuer, on election of the Reporting Person with the consent of the issuer, to pay employee withholding taxes. Such taxes were withheld and reported for the payroll in the period ended August 13, 2021 (for the August 15, 2021 payroll), with the per share value determined as of June 16, 2021, the date of vesting. The grant of the underlying time-based restricted share units, which vest at the rate of 25% per year starting June 16, 2021, was reported on Form 4 filed on June 18, 2020 as to one half of the total grant, and on Form 4 filed on June 26, 2020 as to the remaining one half, which had been granted contingent on increasing the shares reserved for grant under the 2011 Stock Incentive Plan, which was approved the stockholders at a meeting on June 25, 2020.

SEC source: 0001654954-21-007514 · section16.xml · nonDerivative · entry 1

Hull Joseph Stanley · CIK 0001338384 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 775,966

SEC source: 0001654954-21-007511 · section16.xml · nonDerivative · entry 1

Morris Arlene · CIK 0001362520 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 698,666

F1 · price: Weighted average of price paid per share on order, with prices per share ranging from $0.6149 to $0.6217. The reporting person hereby undertakes upon request to provide to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001654954-21-007565 · section16.xml · nonDerivative · entry 1

Morris Arlene · CIK 0001362520 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 698,666

F1 · kind: Amended to reflect open market purchases of non-derivative security.

F2 · price: Weighted average of price paid per share on order, with prices per share ranging from $0.6149 to $0.6217. The reporting person hereby undertakes upon request to provide to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

SEC source: 0001654954-21-007563 · section16.xml · nonDerivative · entry 1

Hull Joseph Stanley · CIK 0001338384 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 775,966

F1 · kind: Amended to reflect open market purchase of non-derivative security.

SEC source: 0001654954-21-007427 · section16.xml · nonDerivative · entry 3

WILLS STEPHEN T · CIK 0001103883 · Executive VP and CFO/COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,734,696

SEC source: 0001654954-21-007427 · section16.xml · nonDerivative · entry 2

WILLS STEPHEN T · CIK 0001103883 · Executive VP and CFO/COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,684,696